(NanoScale®), a leader in advanced chemistry products, services, and
technologies, today announced it has been awarded a contract to develop and
optimize functionalized nanoparticles for imaging of breast cancer by fluorescence
Effective cancer surgery requires that all cancerous tissue be removed. However,
the visual difference between cancerous and healthy tissue is subtle, often
forcing the surgeon to remove excess tissue. NanoScale is leading a team comprising
universities and companies from Kansas to develop and optimize functionalized
nanoparticles that will allow for the diagnosis of breast cancer by fluorescence
optical imaging. This technique will provide the surgeon an immediate differentiation
between cancerous and non-cancerous tissues before any tissue is removed.
“This technique will provide surgeons an improved margin of tissue identification
and cancer detection resulting in superior patient treatment and recovery,”
said Olga Koper, Ph.D., NanoScale’s Chief Technology Officer.
The Phase II SBIR contract is financed 100% by Federal funding at the cost
of $1 million. This project has been funded in whole or in part with Federal
funds from the National Cancer Institute, National Institutes of Health, Department
of Health and Human Services, under Contract No. HHSN261201000111C.
NanoScale Corporation develops and provides high performance advanced chemistry
materials and related services to Customers worldwide. The Company holds a substantial
intellectual property portfolio which includes its patented NanoActive®,
FAST-ACT®, ChemKlenz®, OdorKlenz®, and SpillKlenz™ product
lines and systems. NanoScale produces and sells a wide variety of NanoActive
brand nanocrystalline materials in forms that include dry powders, granules,
and liquid suspensions. FAST-ACT, ChemKlenz, and OdorKlenz Systems are sold
for the prevention, containment, elimination, and remediation of toxic and noxious
chemicals, odors, and related applications.